Apheresis treatment of cryoglobulinemic vasculitis: A multicentre cohort study of 159 patients. Issue 5 (October 2018)

• Record Type: Journal Article
• Authors: Marson, P.; Monti, G.; Montani, F.; Riva, A.; Mascia, M.T.; Castelnovo, L.; Filippini, D.; Capuzzo, E.; Moretto, M.; D'Alessandri, G.; Marenchino, D.; Zani, R.; Fraticelli, P.; Ferri, C.; Quartuccio, L.; De Silvestro, G.; Oreni, L.; Accorsi, P.; Galli, M.
• Is Part Of: Transfusion and apheresis science. Volume 57:Issue 5(2018)
• Page Start: 639
• Page End: 645
• Publication Date: 2018-10
• Subjects: Cryoglobulinemic vasculitis -- Therapeutic apheresis -- Plasma exchange -- Multiorgan involvement -- Cryoglobulinemic glomerulonephritis; Blood -- Transfusion -- Periodicals; Hemapheresis -- Periodicals; 615.39
• DOI: 10.1016/j.transci.2018.06.005
• Languages: English
• ISSNs: 1473-0502

Abstract

Abstract: Objective: To assess the effectiveness of apheresis therapy (AT) in treating the clinical manifestations of patients with complicated cryoglobulinemic vasculitis (CV). Methods: A retrospective cohort study of 159 CV patients attending 22 Italian Centers who underwent at least one AT session between 2005 and 2015. The response to AT was evaluated on the basis of a defined grading system. Results: Peripheral neuropathy was the most frequent clinical condition leading to AT. Therapeutic plasma exchange was used in 70.4% of cases. The outcome of AT was rated very good in 19 cases, good in 64, partial/transient in 40, and absent/not assessable in 36. Life-threatening CV-related emergencies and renal impairment independently correlated with failure to respond to AT. The independent variables associated with an increased risk of death were age at the time of the first AT session, multi-organ life-threatening CV, the presence of renal impairment and failure to respond to AT. The time-dependent probability of surviving until CV-related death in the second year was 84%, with an AHR in patients with absent/not assessable response to AT of 11.25. Conclusion: In this study AT is confirmed to be a safe procedure in patients with CV. Early AT should be considered in patients with severe CV, especially in cases with impending renal involvement, in order to prevent irreversible kidney damage. Although its efficacy in patients with multi-organ failure is limited, AT is the only treatment that can rapidly remove circulating cryoglobulins, and should be considered an emergency treatment.